Clinical trial
Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With…
NCT00448214 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00448214 |
|---|---|
| Title | Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation |
| Official title | Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation - A Double Blind, Parallel, Dose-finding Study in Comparison With Open Label Warfarin |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation |
| Intervention type | Drug |
| Interventions | YM150, warfarin |
| Enrollment | 448 |
| Start date | Mar 1, 2007 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Mar 16, 2007 |
| Last update posted | Dec 19, 2011 |
| Countries | Australia, Hong Kong, Japan, Malaysia, New Zealand, Singapore, South Africa, South Korea, Taiwan, Thailand |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: